Podcast appearances and mentions of Rafael Fonseca

Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA.     Timestamps  01:44 – Quickfire questions  07:25 – CAR-T cell therapy  10:48 – Anti-CD38 antibodies  13:31 – Minimal residual disease  14:30 – Bispecific antibodies  15:31 – Antibody-drug conjugates  19:04 – ASCO 2025  21:24 – Genetic discoveries  26:28 – Fonseca's three wishes 

Featuring a slide presentation and related discussion from Dr Rafael Fonseca, including the following topics: Recent updates from ASH 2024 on the up-front use of anti-CD38 monoclonal antibodies for multiple myeloma (MM) (0:00) Updated data with belantamab mafodotin for the management of MM (12:39) Updated findings with chimeric antigen receptor T cell therapy for the management of MM (17:52) ASH 2024 updates with other novel agents and strategies for the management of MM (21:32) CME information and select publications

Featuring an interview with Dr Rafael Fonseca, including the following topics: Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00) Sequencing bispecific antibodies and CAR T-cell therapy (10:40) Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03) Optimizing maintenance therapy for patients with MM (31:11) Novel management strategies for smoldering myeloma (36:29) Role of anti-CD38 antibodies in the up-front management of MM (41:41) Available data with cereblon E3 ligase modulatory drugs for MM (47:45) CME information and select publications

Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O'Donnell, moderated by Dr O'Donnell, including the following topics: Introduction (0:00) Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05) Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06) Incorporation of Other Novel Agents and Strategies into the Management of Relapsed/Refractory MM — Dr O'Donnell (39:25) CME information and select publications

Neste episódio da série Bate Papo com BB-BI, o analista de Fundos Imobiliários, André Oliveira, CNPI-P, conversa sobre o fundo BRCO11 com o sócio, CIO e diretor de RI da Bresco, Rafael Fonseca. Confira as análises e relatórios do BB-BI em bb.com.br/analises e investalk.bb.com.br

“The HemOnc Pulse” was live for the first time in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in a range of hematologic malignancies. As part of the program, Michael Bishop MD, of the University of Chicago, and Aaron Goodman, MD, of the University of California, San Diego, were joined by Rafael Fonseca, MD, of the Mayo Clinic, to hold a panel on bispecific therapies and explore unanswered questions related to them.

RENDA IMOBILIÁRIA: Libere 30 dias de acesso à lista com os melhores FIIs por apenas 1 REAL. Acesse: https://emprc.us/KxkCe8

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. Here are the shownotes:1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: https://x.com/Rfonsi1/status/1206004966294294528?s=20 2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:https://pubmed.ncbi.nlm.nih.gov/28655925/ 3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):https://pubmed.ncbi.nlm.nih.gov/33129376/ 4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:https://pubmed.ncbi.nlm.nih.gov/36779691/ 5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0 6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:https://pubmed.ncbi.nlm.nih.gov/34388020/ 7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:https://pubmed.ncbi.nlm.nih.gov/34470049/  

Dr. Fonseca offers his thoughts on the future of multiple myeloma (MM) treatment, the ongoing debate between chimeric antigen receptor (CAR)-T therapies and bispecifics, and the latest treatment news on bispecifics, including elranatamab, which had yet to be approved at the time of this recording. The conversation also covers the role of measurable residual disease (MRD), the potential for bispecific therapies to democratize access to advanced treatments, and the intriguing prospect of CAR-T cells potentially replacing hematopoietic stem cell transplants in the first relapse—a scenario reminiscent of lymphoma care. "I don't think it's far-fetched to think that there's going to be a good number of patients with multiple myeloma that will be proposed as CAR T-cell candidates now at the time of first relapse, you know, similar to what has been seen in lymphoma," Dr. Fonseca said. Additionally, the conversation touches on the paradigm shift toward prioritizing deeper responses, including MRD negativity, as a potential avenue to achieve long-term cure for some myeloma patients. "I think the debate of cure versus control in myeloma is pretty much very clear that for those that are capable and those that are fit, the intention should be to try to lead to the deepest responses," he said.

In a Twitter Spaces edition of the Oncology-On-The-Go podcast, Rafael Fonseca, MD and Krina Patel, MD, MSc spoke with CancerNetwork® about how key findings from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingmay impact the treatment paradigm.  Fonseca, director of Innovation and Transformation Relationships at the Mayo Clinic in Phoenix, Arizona and Patel, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, detailed results from the phase 1b RedirecTT-1 trial (NCT04586426) assessing teclistamab-cqyv (Tecvayli) plus talquetamab in those with relapsed/refractory multiple myeloma. In the RedirectTT-1 trial, investigators reported an objective response rate (ORR) of 86.6% across all dose levels and 96.3% at the recommended phase 2 dose. Additionally, the combined complete response (CR) or stringent CR rate was 40.2% and 40.7% at each respective dose level. Another trial of interest that Fonseca and Patel discussed included the phase 2 LINKER-MM1 trial (NCT03761108), evaluating linvoseltamab (REGN5458) in relapsed/refractory multiple myeloma. In the study, the agent elicited an ORR of 71% at the 200 mg dose level. Moreover, the CR rate was 14%, the very good partial response (PR) rate was 29%, and the PR rate was 12%. The estimated 6-month progression-free survival (PFS) rate among patients receiving the regimen was 72.7%. Fonseca and Patel also discussed results from the phase 3 CARTITUDE-4 trial (NCT04181827), comparing ciltacabtagene autoleucel (cilta-cel; Carvykti) with standard of care in lenalidomide (Revlimid)-refractory multiple myeloma. In patients receiving cilta-cel, the median PFS was not reached (NR, 95% CI, 22.8 months-not estimable [NE]) vs 11.8 months (95% CI, 9.7-13.8) among those receiving standard of care. The 12-month PFS rate in each respective arm was 76% vs 49%. Don't forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

La Dra. Nidia Paulina Zapata Canto, hematóloga adscrita al Instituto Nacional de Cancerología en la Ciudad de México, México, junto al Dr. Rafael Fonseca, hematólogo adscrito a la Clínica Mayo en Phoenix, Arizona, nos hablan sobre lo más destacado en hematología en el Congreso Anual ASCO 2023, resaltando los siguientes estudios: CARTITUDE-4 KarMMa Carfilzomib, pomalidomida y dexametasona en el tratamiento de pacientes con MM de alto riesgo MAIA Fecha de grabación: 21 de junio de 2023.                     Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

En este episodio platicamos con Rafael Fonseca sobre los objetivos climáticos globales y nacionales, si en México vamos a lograr la transición energética, qué es la transición energética justa, si se trata de bajar nuestro consumo apagando las luces de nuestra casa o cambiar a fuentes alternativas a los combustibles fósiles, ir en bicicleta al trabajo, comer o no comer carne y todo lo relacionado con energía y emisiones de carbono.

Over the past 30 years, cancer death rates have declined by 33%. Ahead of World Cancer Day, hematologist Dr. Rafael Fonseca joins the podcast to talk about the latest innovations and improvements in cancer care delivery that have contributed to this decline.Plus, many patients with chronic diseases depend on employer-sponsored health plans. But losing a job and the health insurance that comes with it can leave patients scrambling for a plan that doesn't interrupt their care. Montana Kirby shares her experience with this situation, what to know about COBRA health plans, and her advice for patients who may find themselves in a similar scenario.Hosts: Terry Wilcox, CEO, Patients RisingDr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public InterestGuests:Rafael Fonseca, MD, Chief Innovation Officer, Mayo Clinic in ArizonaMontana Kirby, Patient AdvocateSherri Gorbett, Patient CorrespondentLinks: States jump into fight over prior authorization requirementsWhen Prior Authorization Practices Go Too FarUS cancer death rates falls 33% since 1991, partly due to advances in treatment, early detection and less smoking, report saysWhat young adults need to know about health insurance enrollmentNeed help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest's current or previous employers. 

Featuring perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics: Front-Line Treatment of Multiple Myeloma (MM)  Introduction (0:00) Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49) Cases: An otherwise healthy man in his late 80s with NDMM who is disinclined to undergo aggressive therapy and a transplant-ineligible woman in her late 70s with NDMM — Erik Rupard, MD and Hans Lee, MD (10:05) Dr Orlowski presentation (15:45) Integration of Novel Therapies into the Management of Relapsed/Refractory MM  Cases: A transplant-eligible man in his late 60s with well-controlled HIV-1 and standard-risk NDMM and a man in his late 60s with high-risk, t(4;14) multiregimen-refractory MM with travel limitations who receives belantamab mafodotin — Neil Morganstein, MD and Syed Farhan Zafar, MD (29:19) Cases: A woman in her early 70s who receives daratumumab, bortezomib and dexamethasone for relapsed MM 6 years after RVd followed by autologous stem cell transplant and maintenance bortezomib, and a man in his mid 50s with NDMM who received RVd followed by maintenance lenalidomide, which was discontinued by the patient after 1 year — Henna Malik, MD and Dr Rupard (35:50) Dr Fonseca presentation (41:57) Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM  Case: A man in his early 70s with NDMM who receives induction daratumumab/RVd — Spencer H Bachow, MD (52:27) Cases: A woman in her early 60s with relapsed MM and pathologic fractures who received induction daratumumab/Rd and palliative radiation therapy for bone disease, and a woman in her mid 70s with refractory MM 6 months after induction daratumumab/RVd lite — Dr Bhatnagar and Kimberly Ku, MD (57:00) Dr Raje presentation (1:01:12) Bispecific Antibodies in the Treatment of MM  Case: A man in his early 70s with t(4;14) NDMM who initiates RVd, which is put on hold to treat severe depression — Warren S Brenner, MD (1:14:38) Case: A woman in her mid 70s with multiregimen-refractory del(17p) MM who is considered for BCMA-directed therapy — Dr Bachow (1:16:28) Dr Berdeja presentation (1:22:18) Other Investigational Novel Agents for MM  Case: A woman in her mid 80s with congestive heart failure and t(4;14), t(11;14) and t(14;16) MM who receives dose-reduced RVd and develops chalazion eye toxicity — Jennifer L Dallas, MD (1:36:23) Dr Lonial presentation (1:39:34) CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, including key clinical presentations and papers in breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Harold Burstein, Ibiayi Dagogo-Jack, Rafael Fonseca, Brad Kahl, Rutika Mehta, Craig Moskowitz, Joyce O'Shaughnessy, Krina Patel, Philip Philip, Suresh Ramalingam and Sandy Srinvas, moderated by Dr Neil Love.

Rafael Fonseca, MD, Getz Family Professor of Cancer, Phoenix, AZ Recorded on June 30, 2022 In this episode, Dr. Rafael Fonseca, from the Mayo Clinic in Arizona, joins Dr. Ken Miller to breakdown the complex and complicated nature of genomics and molecular profiling. He discusses the role of molecular profiling in treating blood cancers, explains how we integrate genomics into the standard of care for people living with cancer, the potential of false negatives, provides examples of clinical applications, financial implications, and resources for patients. Tune in to the conversation today! This podcast episode is supported by Blueprint Medicines Corporation.

La Dra. Nidia Paulina Zapata Canto, hematólogo adscrita al Instituto Nacional de Cancerología en la Ciudad de México, México tiene como invitado especial en este episodio de “Las 5 actualizaciones en…” al Dr. Rafael Fonseca, hematólogo adscrito a la Clínica Mayo en Phoenix, Arizona para comentar lo más destacado sobre el mieloma múltiple. Dentro de su conversación, los expertos resuelven las siguientes interrogantes: · ¿Cuáles son las indicaciones para los anti BCL-2 en el tratamiento de los pacientes con mieloma múltiple? · ¿Cuándo se puede utilizar un inhibidor oral en primera línea y cuándo sustituiría al inhibido intravenoso? · ¿Cuál sería la mejor línea de tratamiento para los pacientes fit y no fit? · Entre otras… Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

While not yet mainstream in the community setting, measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.Our guests—Drs. Rafael Fonseca and Tara Graff—discuss the benefits of MRD testing for these specific patient populations, the importance of training the multidisciplinary care team, and the promise of MRD testing to improve patient outcomes as its adoption continues to grow. Guests: Rafael Fonseca, MD Professor of Medicine, Mayo Clinic Scottsdale, Arizona Tara Graff, DO Medical Oncologist, Mission Cancer and BloodDes Moines, Iowa  This podcast is produced as part of the ACCC MRD Testing Implementation Roadmaps education project and is funded by Adaptive Biotechnologies.Resources: MRD Testing Implementation RoadmapsMRD Testing Implementation Roadmap for B-cell Acute Lymphoblastic LeukemiaMRD Testing Resource LibraryMultidisciplinary Multiple Myeloma CareBiomarkers in Hematologic Malignancies: A Focus on CLL and Multiple MyelomaMultidisciplinary Chronic Lymphocytic Leukemia Care

Chadi welcomes back Rafael Fonseca, (@Rfonsi1), MD, interim director of Mayo Clinic Cancer Center, and Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, to debate whether smoldering multiple myeloma should be treated. They begin by agreeing on a definition of the disease, listing patient characteristics that may warrant consideration for early intervention, and stating the importance of improving the ability to predict progressing disease. The trio then debate treatment in specific example circumstances and the overall consensus within the myeloma world, the practicality of clinical trials for smoldering disease, and so much more in this testy and thought-provoking dialogue.

On the show today: Dr. Rafael Fonseca is a professor of medicine at Mayo Clinic who focuses on Multiple Myeloma with a sidebar hobby dabbling in Ethics Health Economics. Fun fact of the day, he's a Google Scholar, has his own Wikipedia page, courtesy of a birthday gift from his son, and — as a self-proclaimed pathological optimist — hopes to spread empathy throughout the medical community while protecting the rights of patients, so they can make the best decisions for themselves and no one else. Bonus points for him being a hysterically refreshing voice on Twitter. Enjoy the show.For more information, visit https://OffScripMedia.com and follow @MZOutofPatients, @MatthewZachary, @VaxOnPod, and @OffScripMedia on Twitter.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The most effective treatments are often out of reach for patients. Big news came from the FDA announcing the approval of CAR-T therapies for multiple myeloma patients, but drug assessments from third-party groups are concerning. Will patients be able to access these life-saving treatments?Multiple myeloma oncologist Dr. Rafael Fonseca highlights the benefits of CAR-T therapies, the future of these advanced technologies, and the impossible task of putting a dollar value on patient quality of life. We also hear from multiple myeloma patient and advocate Dale Hopkins on how designer drugs like CAR-T could be a game-changer for his treatment regimen. Guest:Rafael FonsecaInterim Director, Mayo Clinic Cancer CenterRafael Fonseca, M.D., is the interim director of Mayo Clinic Cancer Center and the director for Innovation and Transformational Relationships at Mayo Clinic's Arizona campus.Dr. Fonseca has a broad range of research interests, including clinical trials for the treatment of myeloma and related conditions, a better understanding of the genetics of myeloma and related conditions (including the clinical implications), new drug development (including harnessing the cells' metabolism to develop effective therapies), myeloma bone disease, pharmacoeconomics, and policy. The cumulative research efforts of Dr. Fonseca's laboratory have led to a better understanding of myeloma and related diseases, and unlocked novel treatment options for patients and provided context for the pharmacoeconomic implications of new therapies.Links:Dr. Rafael FonsecaDale Hopkins BlogFDA Approves First CAR-T Cell Therapy for Multiple Myeloma ICER’s Review on Multiple Myeloma Limiting Medicaid Access to Accelerated Approval Drugs: Costs and ConsequencesPatient Correspondent: Megan Claire-ChasePatients Rising Concierge Need help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.

Featuring slide presentations and related discussion from Drs Rafael Fonseca and Jonathan L Kaufman, including the following topics: Customized induction and maintenance approaches for newly diagnosed MM; select new developments in relapsed/refractory disease — Rafael Fonseca, MD (0:00) Newly approved and promising investigational agents for patients with relapsed/refractory MM — Jonathan L Kaufman, MD (57:40) CME information and select publications

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 1: Consolidation and Maintenance Therapy in Newly Diagnosed MM — Role of MRD Testing — Dr Fonseca. CME information and select publications

Vincent Rajkumar, (@VincentRK), MD, hematologist at the Mayo Clinic (Rochester, MN), joins the show to guest host a debate between Sagar Lonial (@SagarLonialMD), MD, FACP, chief medical officer of Winship Cancer Institute of Emory University, and Rafael Fonseca, (@Rfonsi1), MD, interim director of Mayo Clinic Cancer Center. These multiple myeloma “gurus” dive into imaging, smoldering disease, endpoints, maintenance, minimal residual disease, and so much more.

In this episode of Real World Talk, host Kevin Keogh talks to Dr. Rafael Fonseca, a hematologist who specializes in multiple myeloma, and Interim Director of the Mayo Clinic's Cancer Center. They discuss the gulf between the idealized world of clinical trials and the reality experienced by patients with an incurable cancer like multiple myeloma — and how real world data can help bridge the gap. “I wish we all lived in a world where Phase III trials could be completed in one day and where we had Phase III trials for every patient situation, but we just don't,” Dr. Fonseca says. “You have to realize that there is a reality when it comes to how much you can actually do.” For example, weighing the clinical implications of giving a patient a follow-up treatment that may interact with previous drugs. “We can apply some of the real world datasets to see if the actual performance in the clinical practice really mirrors what we're seeing in the clinical trials,” Dr. Fonseca says. They also discuss calculating the real cost of treatments using a holistic method, and why Dr. Fonseca believes expensive drugs lead to more innovations in the long term.

Confira as dicas que o publicitário Rafael Fonseca deu em entrevista! --- Send in a voice message: https://anchor.fm/kellenmelo/message

Vincent Rajkumar, MD, and Rafael Fonseca, MD, both multiple myeloma specialists at Mayo Clinic, discuss the prospect of opening the country before a vaccine is developed for COVID-19; whether the decisions should be made on a county-, state-, or regional-level; and the critical need for a "TTP" approach: widespread adequate Testing, contact Tracing, and PPEs.

Chadi welcomes back Rafael Fonseca, MD, interim executive director, Mayo Clinic Comprehensive Cancer Center, to discuss the steps that large cancer centers should take to protect their patients as well as staff from COVID-19 infection, specific measures that Mayo Clinic has taken for developing in-house testing, and more.

Rafael Fonseca, MD, and Saurabh Jha, MD, debate the benefits and disadvantages of a third-party vs single payer system, whether Medicare has been a successful program for qualifying patients. and the fairness of judging the health care system based on life expectancy. To read more about our host Chadi Nabhan and access exclusive materials and information about guests, visit journalofclinicalpathways.com/podcasts/outspoken-oncology. Journal of Clinical Pathways is the exclusive producer of the Outspoken Oncology podcast.

During this episode of Tech Qualified, we talk with Rafael Fonseca, Vice President of Product Management and Marketing at Artel Video Systems. Rafael Fonseca discusses what Artel has brought to the industry in the last 30 years, what it means to them to be ‘good citizens,’ what Artel is accomplishing on the product and marketing side, how they are embracing IP, and how IP is benefiting end-users in the broadcast industry. Episode Highlights:   Rafael Fonseca shares some of his career experience and his current work.  Who is Artel’s ideal customer and how do they help them? How is the industry changing and how have standards been implemented?   What does IP open up for the end-consumer?  How does Artel compare to competitors?   What is Rafael up to on the product and marketing side?  What is happening these days between broadcast and IT? What is Rafael’s mindset on how to differentiate the company from competitors?   How does Artel develop data and content?  Are they doing a lot of one-to-one content?   Do they leverage content writers internally or externally?  Once marketing assets are available, what is the communication across teams?  Is he finding that customers need more information to make decisions? What about buying committees?   What are some of the major marketing initiatives that Artel is gearing up for? 3 Key Points:   Artel aids broadcasters and media companies to transport their content from the venue and the contribution side of things all the way to the distribution as well as organizations that are media generators, broadcasters, and live events.    End-users will benefit from IP by seeing the quality and richness of information being better, improved data and social media experiences, more personalized experiences and more interaction.     Sales channels that Artel rely on include: direct channels, a direct sales force, partners, and end-customers.

Rafael Fonseca, MD is a consultant in the Division of Hematology and Oncology at the Mayo clinic in Arizona and a visiting healthcare fellow at Goldwater Institute. Dr. Fonseca discusses the fiduciary responsibility of the physician to the patient.

STEP therapy is an approach in managed medical care to minimize costs of prescription drugs. The program allows patients to begin therapy with the most cost-effective drugs and work their way up to more costly therapies only if necessary. It is also called "step protocol" or "fail first" and is a type of prior authorization requirement. Upward trends for prescription medications in the United States has led to an increased pressure on health care providers to keep medication costs down while maintaining drug availability. The cost controlling measures could impact cancer therapies for all patients, but it may be a particular challenge for myeloma patients who tend to used combination therapies in a serial fashion. Learn more about this and other issues about cost in myeloma care with Dr. Rafael Fonseca, Chair the Mayo Clinic Scottsdale program.  Dr. Rafael Fonseca is the Chair of the Department of Internal Medicine and Professor of Medicine at the Mayo Clinic in Scottsdale. He is also Getz Family Professor of Cancer in Mayo Clinic College of Medicine and Science in the Department of Education Administration. He is a Distinguished Mayo Investigator since 2010 and is also a Consultant in the Divisions of Hematology/Oncology and Basic Sciences Research Laboratories at the Mayo Clinic. Dr. Fonseca is an Editorial Board Member for the publication Genes, Chromosomes and Cancer. Dr. Fonseca is also on the Mayo Clinic Arizona Executive Operations Team  and Editorial Board.

In this interview, Lucía Delgado Sanchez (MPP '18) travels to Mexico and interviews Rafael Fonseca about his yearlong work with the United Nations Small Grants Program in the Dominican Republic. Credits:Lucía Delgado Sanchez for interviewingPeter Biava for sound productionDavid Raban for editingShirin Raban for cover design

In this interview, Lucía Delgado Sanchez (MPP '18) travels to Mexico and interviews Rafael Fonseca about his yearlong work with the United Nations Small Grants Program in the Dominican Republic. Credits:Lucía Delgado Sanchez for interviewingPeter Biava for sound productionDavid Raban for editingShirin Raban for cover design

https://accadandkoka.com/wp-content/uploads/2018/08/Fonseca-image-e1535051910281.jpg ()Dr. Rafael Fonseca https://accadandkoka.com/wp-content/uploads/2018/08/jatucker-e1535051981431.jpg ()Dr. John Tucker Do medical journals apply scientific standards selectively?  On the subject of the effect of pharmaceutical lunch gifts on physician behavior, all that may be required from a paper is that the conclusions drawn be compatible with the expected narrative—even if the data presented suggests the opposite.  Joining us are Rafael Fonseca and John Tucker who shared with us their eye-opening analysis of a recent article published in JAMA Internal Medicine and the fascinating reaction to their analysis from journal editors and from the community at large. GUESTS: Rafael Fonseca, MD: https://twitter.com/Rfonsi1?lang=en (Twitter) and http://liberteriandoc.tumblr.com/ (Website) John Tucker, PhD: https://twitter.com/JohnTuckerPhD?lang=en (Twitter) LINKS: Rafael Fonseca and John Tucker. http://thehealthcareblog.com/blog/2018/07/21/are-doctors-bribed-by-pharma-an-analysis-of-data/ (Are doctors bribed by Pharma: A critical analysis of a recent study by Hadland and colleagues) (In The Health Care Blog). Rafael Fonseca and Jeffrey Singer.  https://www.cato.org/blog/politics-confirmation-bias-opioids (Politics, Confirmation Bias, and Opioids).  (Cato Institute blog) Rafael Fonseca. https://www.ncbi.nlm.nih.gov/pubmed/23234526 (How physicians interpret research funding disclosures.) (New England Journal of Medicine) WATCH ON YOUTUBE: https://youtu.be/-ZqYoIqSpZg (Watch the episode) on our YouTube channel Support this podcast

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Stephen Maxted Ansell, Matthew S Davids, Rafael Fonseca, Paul G Richardson, Laurie H Sehn and Anas Younes. | For more information, visit: http://www.researchtopractice.com/ASCOHem18

A new tool for multiple myeloma patients is coming in June! Join us as we discuss the Myeloma Crowd's new initiative called HealthTree with Rafael Fonseca, MD of the Mayo Clinic in Scottsdale.  HealthTree will help myeloma patients understand their personally relevant treatment options, find clinical trials, track lab data and help accelerate research towards a cure.   Over 80% of myeloma patients are treated by general oncologists, yet data shows that patients who see myeloma specilists can live 38% longer. This is true because myeloma is a highly complex cancer to treat. HealthTree was designed to help you have better discussions with your doctor about options that may be available to you so you can receive optimal care for your specific situation. The tool also allows patients and researchers to view anonymous long-term data about the collective patient experience, providing new hypotheses about better patient care.  This summer, we will be canvasing the United States and hosting hands-on HealthTree workshops to help myeloma patients learn how to use the tool with one-on-one help. The HealthTree Summer Tour 2018 begins on June 1 in over 50 cities in the United States. Patients are invited to bring laptops and attend the HealthTree workshops where they can receive one-on-one support. Learn more and find city locations on www.myelomacrowd.org/healthtree. Special thanks to our episode sponsor, Takeda Oncology.

Proceedings from a Clinical Investigator Roundtable Discussion with Rafael Fonseca, MD and Noopur Raje, MD. Moderated by Neil Love, MD. Produced by Research To Practice.

Proceedings from a Clinical Investigator Roundtable Discussion with Rafael Fonseca, MD and Noopur Raje, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Rafael Fonseca, MD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with Anas Younes, MD, B Douglas Smith, MD, Rafael Fonseca, MD and John P Leonard, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Esta semana o João Biscaia, a Maria Martins e o Rafael Fonseca falam do novo álbum dos SUUNS, de Linda Perhacs e ainda dão algumas sugestões culturais. Escutem-nos!

A emissão desta semana é conduzida por Ana Santos, que vai ser acompanhada por Rafael Fonseca e João Carvalho. Juntos vêm falar-nos do festival de animação Monstra e das bandas Los Negros e Criatura. Ouve-nos!

Discussion of 66 Presentations and Posters from the 2013 American Society of Hematology Annual Meeting in New Orleans, Louisiana. Featuring interviews with Rafael Fonseca, MD, Brad S Kahl, MD, Moshe Talpaz, MD, Hagop M Kantarjian, MD and Christopher Flowers, MD, MS conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Interview with Rafael Fonseca, MD conducted by Neil Love, MD. Produced by Research To Practice.

Listen to cytogenetics and genomics expert Dr. Rafael Fonseca, MD of the Mayo Clinic in Scottsdale share the latest in his myeloma research and his open clinical trials. 

Listen to cytogenetics and genomics expert Dr. Rafael Fonseca, MD of the Mayo Clinic in Scottsdale share the latest in his myeloma research and his open clinical trials. 

Panel discussion on challenging cases of multiple myeloma from the 2012 ONS Annual Congress featuring Melissa Alsina, MD, Beth Faiman, PhDc, MSN, APRN-BC, AOCN, Rafael Fonseca, MD and Kena C Miller, MSN, FNP-BC moderated by Neil Love, MD. Produced by Research To Practice. CME Information and Program PDF. Produced by Research To Practice.

Rounds with the Investigators: National Research Leaders Provide Their Perspectives on the Management of Actual Patients with Multiple Myeloma. Roundtable discussion with Rafael Fonseca, MD and Ravi Vij, MD moderated by Neil Love, MD. Produced by Research To Practice.

Rounds with the Investigators: National Research Leaders Provide Their Perspectives on the Management of Actual Patients with Multiple Myeloma. Featuring roundtable discussions with Rafael Fonseca, MD and Ravi Vij, MD and Jeffrey L Wolf, MD and Jeffrey A Zonder, MD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma. Similar to bortezomib, but administered orally, MLN9708 is the first oral drug to go into clinical trial for myeloma. MLN9708 is boron-based making it a reversible inhibitor. Current trials using the experimental drug aim to determine the dosage and efficacy in myeloma. Patients receiving the drug have already been heavily treated with commonly available agents and had high efficacy, with very low rates of neuropathy, when used in combination with other drugs. en Español

Exploring the Clinical Decisions of Community-Based Oncologists and Hematologists in the Management of Multiple Myeloma and Follicular Lymphoma. Featuring a panel discussion with Stephanie A Gregory, MD, Sagar Lonial, MD, Kenneth C Anderson, MD, Bruce D Cheson, MD, Myron S Czuczman, MD and Rafael Fonseca, MD moderated by Neil Love, MD; and interviews with Sagar Lonial, MD and Stephanie A Gregory, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Panel discussion with Stephanie A Gregory, MD, Sagar Lonial, MD, Kenneth C Anderson, MD, Bruce D Cheson, MD, Myron S Czuczman, MD and Rafael Fonseca, MD moderated by Neil Love, MD. Produced by Research To Practice.

An Audio Review Journal for Nurses featuring interviews with John P Leonard, MD, Rafael Fonseca, MD, Kena C Miller, MSN, FNP and Mollie Moran, MSN, CNP, AOCNP conducted by Neil Love, MD. CNE Information and Program PDF. Produced by Research To Practice.

An Audio Review Journal for Nurses. Management of Non-Hodgkin’s Lymphomas and Multiple Myeloma. Interview with Rafael Fonseca, MD conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/POCMM110 – Patterns of Care – Management of Multiple Myeloma. Interview (part 1) with Rafael Fonseca, MD conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/POCMM110 – Patterns of Care – Management of Multiple Myeloma. Featuring interviews with Irene M Ghobrial, MD Sagar Lonial, MD and Rafael Fonseca, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

ResearchToPractice.com/CaCU209 – Discussion of 65 Presentations and Posters from the 2009 Annual Oncology Meeting in Orlando, Florida. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ResearchToPractice.com/CaCU209 – Discussion of 65 Presentations and Posters from the 2009 Annual Oncology Meeting in Orlando, Florida. CME Information and Program PDF. Featuring interviews with Charles D Blanke, MD, Everett E Vokes, MD, Rafael Fonseca, MD, Harold J Burstein, MD, PhD, Deborah K Armstrong, MD, William K Oh, MD and Myron S Czuczman, MD conducted by Neil Love, MD. Produced by Research To Practice.

Guest: Philip Greipp, MD Host: Bruce Bloom, DDS, JD From the 5th Mayo Clinic State of the Art Symposium on Hematologic Malignancies, your host Dr. Bruce Bloom interviews its organizers and speakers; Dr. Phil Greipp, Dr. David Steensma, Dr. Rafael Fonseca, and Dr. Ruben Mesa in discussing the origin, growth, and goals of the conference.